Literature DB >> 26443211

The Development of TALE Nucleases for Biotechnology.

David G Ousterout1, Charles A Gersbach2,3,4.   

Abstract

The development of a facile genome engineering technology based on transcription activator-like effector nucleases (TALENs) has led to significant advances in diverse areas of science and medicine. In this review, we provide a broad overview of the development of TALENs and the use of this technology in basic science, biotechnology, and biomedical applications. This includes the discovery of DNA recognition by TALEs, engineering new TALE proteins to diverse targets, general advances in nuclease-based editing strategies, and challenges that are specific to various applications of the TALEN technology. We review examples of applying TALENs for studying gene function and regulation, generating disease models, and developing gene therapies. The current status of genome editing and future directions for other uses of these technologies are also discussed.

Entities:  

Keywords:  Gene editing; Gene targeting; Gene therapy; Genome engineering

Mesh:

Substances:

Year:  2016        PMID: 26443211      PMCID: PMC5316914          DOI: 10.1007/978-1-4939-2932-0_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  126 in total

1.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Authors:  Jizhong Zou; Prashant Mali; Xiaosong Huang; Sarah N Dowey; Linzhao Cheng
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

2.  De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks.

Authors:  Magdy M Mahfouz; Lixin Li; Md Shamimuzzaman; Anjar Wibowo; Xiaoyun Fang; Jian-Kang Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

3.  Targeted genome editing across species using ZFNs and TALENs.

Authors:  Andrew J Wood; Te-Wen Lo; Bryan Zeitler; Catherine S Pickle; Edward J Ralston; Andrew H Lee; Rainier Amora; Jeffrey C Miller; Elo Leung; Xiangdong Meng; Lei Zhang; Edward J Rebar; Philip D Gregory; Fyodor D Urnov; Barbara J Meyer
Journal:  Science       Date:  2011-06-23       Impact factor: 47.728

4.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

5.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

6.  Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase.

Authors:  Charles A Gersbach; Thomas Gaj; Russell M Gordley; Andrew C Mercer; Carlos F Barbas
Journal:  Nucleic Acids Res       Date:  2011-06-07       Impact factor: 16.971

7.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.

Authors:  Kosuke Yusa; S Tamir Rashid; Helene Strick-Marchand; Ignacio Varela; Pei-Qi Liu; David E Paschon; Elena Miranda; Adriana Ordóñez; Nicholas R F Hannan; Foad J Rouhani; Sylvie Darche; Graeme Alexander; Stefan J Marciniak; Noemi Fusaki; Mamoru Hasegawa; Michael C Holmes; James P Di Santo; David A Lomas; Allan Bradley; Ludovic Vallier
Journal:  Nature       Date:  2011-10-12       Impact factor: 49.962

8.  Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.

Authors:  David G Ousterout; Pablo Perez-Pinera; Pratiksha I Thakore; Ami M Kabadi; Matthew T Brown; Xiaoxia Qin; Olivier Fedrigo; Vincent Mouly; Jacques P Tremblay; Charles A Gersbach
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

9.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering.

Authors:  Sandrine Boissel; Jordan Jarjour; Alexander Astrakhan; Andrew Adey; Agnès Gouble; Philippe Duchateau; Jay Shendure; Barry L Stoddard; Michael T Certo; David Baker; Andrew M Scharenberg
Journal:  Nucleic Acids Res       Date:  2013-11-26       Impact factor: 16.971

10.  Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies.

Authors:  Charles A Gersbach; Thomas Gaj; Carlos F Barbas
Journal:  Acc Chem Res       Date:  2014-05-30       Impact factor: 22.384

View more
  13 in total

Review 1.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

Review 2.  Gene Editing for Treatment of Neurological Infections.

Authors:  Martyn K White; Rafal Kaminski; Hassen Wollebo; Wenhui Hu; Thomas Malcolm; Kamel Khalili
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 3.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

Review 4.  Targeted protein degradation: A promise for undruggable proteins.

Authors:  Kusal T G Samarasinghe; Craig M Crews
Journal:  Cell Chem Biol       Date:  2021-05-17       Impact factor: 9.039

Review 5.  Applications of Alternative Nucleases in the Age of CRISPR/Cas9.

Authors:  Tuhin K Guha; David R Edgell
Journal:  Int J Mol Sci       Date:  2017-11-29       Impact factor: 5.923

Review 6.  CRISPR/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS).

Authors:  Ewa Kruminis-Kaszkiel; Judyta Juranek; Wojciech Maksymowicz; Joanna Wojtkiewicz
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

7.  TALEN-Mediated FLAG-Tagging of Endogenous Histone Methyltransferase DOT1L.

Authors:  Cheng An; Guangjing Zhu; Suzanne N Martos; Xue Feng; Haimou Zhang; Yankai Jia; Zhibin Wang
Journal:  Adv Biosci Biotechnol       Date:  2017-09-22

Review 8.  Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.

Authors:  Jonathan H Esensten; Jeffrey A Bluestone; Wendell A Lim
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

9.  Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches.

Authors:  Tiffany Leidy-Davis; Kai Cheng; Leslie O Goodwin; Judith L Morgan; Wen Chun Juan; Xavier Roca; S Tiong Ong; David E Bergstrom
Journal:  Sci Rep       Date:  2018-10-09       Impact factor: 4.379

10.  Homologous recombination-mediated targeted integration in monkey embryos using TALE nucleases.

Authors:  Chu Chu; Zhaohui Yang; Jiayin Yang; Li Yan; Chenyang Si; Yu Kang; Zhenzhen Chen; Yongchang Chen; Weizhi Ji; Yuyu Niu
Journal:  BMC Biotechnol       Date:  2019-01-15       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.